1210
|
EcoXyn-4V
|
E.coli Infections
|
Escherichia coli
|
Bioconjugate
|
GlycoVaxyn AG
|
Clinical - Phase 1
|
Intramuscular
|
NA
|
NCT02289794
|
1211
|
Recombinant (dsc14CfaE-sCT2/LTB5)
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Intradermal
|
NA
|
NCT01644565
|
1212
|
Recombinant (dscCfaE)
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
U.S. Army Medical Research and Development Command
|
Clinical - Phase 1
|
Transcutaneous
|
NA
|
NCT01382095
|
1213
|
CVD 1208S-122
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
University of Maryland, Baltimore
|
Clinical - Phase 1
|
Oral
|
32257392
|
NCT04634513
|
1214
|
VLA1701
|
E.coli Infections
|
Escherichia coli
|
NA
|
Valneva Austria GmbH
|
Clinical - Phase 2
|
Oral
|
NA
|
NCT03576183
|
1215
|
dmLT
|
E.coli Infections
|
Escherichia coli
|
Recombinant
|
National Institute of Allergy and Infectious Diseases (NIAID)
|
Clinical - Phase 1
|
Sublingual
|
NA
|
NCT02052934
|
1216
|
ACE527
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
TD Vaccines A/S
|
Clinical - Phase 1
|
Oral
|
NA
|
NCT00901654
|
1217
|
ExPEC9V
|
E.coli Infections
|
Escherichia coli
|
Bioconjugate
|
Janssen Research & Development, LLC
|
Clinical - Phase 3
|
Intramuscular
|
NA
|
NCT04899336
|
1218
|
ACAM2007
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
1219
|
ACAM2010
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
1220
|
ACAM2017
|
E.coli Infections
|
Escherichia coli
|
Live attenuated
|
NA
|
Clinical - Phase 1
|
Oral
|
17566016
|
NA
|
1221
|
ETEC expressing CFA/I and CFA/II
|
E.coli Infections
|
Escherichia coli
|
Inactivated
|
NA
|
Clinical
|
Oral
|
NA
|
NA
|